Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AKOS-22 is a potent mitochondrial protein VDAC1 (voltage-dependent anion channel 1) inhibitor (Kd=15.4 μM). AKOS-22 protects against mitochondrial dysfunction[1]. AKOS-22 interacts with VDAC1 and inhibiting both VDAC1 oligomerization and apoptosis.
产品描述 | AKOS-22 is a potent mitochondrial protein VDAC1 (voltage-dependent anion channel 1) inhibitor (Kd=15.4 μM). AKOS-22 protects against mitochondrial dysfunction[1]. AKOS-22 interacts with VDAC1 and inhibiting both VDAC1 oligomerization and apoptosis. |
靶点活性 | VDAC1:(kd)15.4 μM |
体外活性 | AKOS-22 inhibits selenite-induced VDAC1 oligomerization, Cyto c release and apoptosis in HEK-293 cells (IC50=3.3-3.6 μM), and which prevents the elevation of [Ca2+]I associated with apoptosis induction, and thus Ca2+ accumulation by the mitochondria[1]. AKOS-22 (5-20 μM; 2 hours) inhibits both VDAC1 oligomerization and apoptosis in a concentration-dependent manner (IC50=7.5 μM)[1]. AKOS-22 (30 μM, 2 h) inhibits cisplatin-induced VDAC1 oligomerization and apoptosis in neuroblastoma cell line SH-SY5Y. |
分子量 | 467.87 |
分子式 | C22H21ClF3N3O3 |
CAS No. | 878983-38-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AKOS-22 878983-38-1 Others AKOS22 AKOS 22 Inhibitor inhibitor inhibit